OncoMatch/Clinical Trials/NCT06234007
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Is NCT06234007 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine for locally advanced rectal cancer.
Treatment: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine — To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CT4B, CN2 (AJCC 8th edition)
Clinical tumor (cT) stage cT4a or cT4b (according to the AJCC, 8th edition); Clinical lymph node (cN) stage cN2 (according to the AJCC, 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any anti-tumor treatment
Have not received any anti-tumor treatment for rectal cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
Lab requirements
Blood counts
Neutrophil count ≥ 1.5×10^9/L; Platelet count ≥ 100×10^9/L; Hemoglobin ≥ 90 g/L; White blood cell count ≥ 3.0×10^9/L
Kidney function
Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min (Cocheroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5×ULN (Gilbert's syndrome subjects, ≤3×ULN; Tumor liver metastasis, total bilirubin ≤3×ULN); ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN (≤5×ULN for patients with liver metastases)
Cardiac function
Doppler ultrasound assessment: left ventricular ejection fraction (LVEF)≥50%
Normal major organ function, including: Routine blood test ...; Blood biochemical tests ...; Coagulation function ...; Doppler ultrasound assessment: left ventricular ejection fraction (LVEF)≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06234007 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT4B or CN2 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages